Global Partners

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Global Partners LP Q2 2026 Earnings Call Summary

THW: The GLP-1 Market Can Help Support The 10% Yield

GLP-1 treatment reduces sickness absence

GLP-1 drugs have transformed the treatment of type 2 diabetes and obesity. As governments and insurers debate whether and how to cover GLP-1 drugs, much of the discussion focuses on health spending. But obesity and diabetes also impose costs through the labour market. Using linke…

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Novo Nordisk vs. Eli Lilly: Q2 prints, valuations and the GLP-1 race